Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND Lantus (Insulin glargine) AND Insulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    168 result(s) found for: Diabetes AND Lantus (Insulin glargine) AND Insulin. Displaying page 7 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-017814-56 Sponsor Protocol Number: NN5401-3599 Start Date*: 2011-01-31
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart once daily (OD) and insulin glargine OD both in combination ...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2013-004737-33 Sponsor Protocol Number: 5706 Start Date*: 2018-05-16
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabe...
    Medical condition: haemodialyzed patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10049746 Insulin-requiring type II diabetes mellitus LLT
    18.0 100000004865 10018874 Haemodialysed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019223-55 Sponsor Protocol Number: H9X-MC-GBDD Start Date*: 2010-07-12
    Sponsor Name:Lilly S.A.
    Full Title: Comparación del efecto de LY2189265 frente a insulina glargina, administrados en combinación con insulina lispro, para el tratamiento hasta alcanzar el objetivo, en pacientes con diabetes mellitus ...
    Medical condition: Diabetes Mellitus Tipo 2
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-000497-80 Sponsor Protocol Number: H7U-MC-IDAV Start Date*: 2007-07-27
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabete...
    Medical condition: Male or female nonsmoking patients 18 years of age or older who have had type 1 diabetes mellitus for at least 24 months at study entry and are taking at least 2 or 3 preprandial injections per day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000349-40 Sponsor Protocol Number: H8O-MC-GWAO Start Date*: 2004-05-19
    Sponsor Name:ELI LILLY
    Full Title: Efficacy of Exenatide Compared with Insulin Glargine in Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012607 5
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005866-39 Sponsor Protocol Number: I2R-MC-BIDJ Start Date*: 2012-04-18
    Sponsor Name:Lilly S.A.
    Full Title: A Comparison of LY2605541 versus Insulin Glargine Alone or in Combination with Pre study Oral Antihyperglycemic Medications in Patients with Type 2 Diabetes Mellitus Previously Treated with Basal I...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-000521-19 Sponsor Protocol Number: EXT_LANTU_C_02761 Start Date*: 2008-08-08
    Sponsor Name:sanofi aventis Groupe
    Full Title: Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin ...
    Medical condition: Type 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053247 Insulin-requiring type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PT (Completed) AT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000122-31 Sponsor Protocol Number: Lantu_L_00722 Start Date*: 2006-03-09
    Sponsor Name:Aventis Pharma s.r.o.
    Full Title: Srovnání fluktuací glykemií při bazální substituci humánním inzulínem NPH a inzulínovým analogem glargine (kontinuální měření glykemií)
    Medical condition: Type 1 and 2 diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-007026-19 Sponsor Protocol Number: LANTU_L_04211 Start Date*: 2009-04-24
    Sponsor Name:Aventis Pharma Ltd trading as sanofi-aventis
    Full Title: COMPARISON OF A BASAL PLUS ONE INSULIN REGIMEN (INSULIN GLARGINE/INSULIN GLULISINE) WITH A BIPHASIC INSULIN REGIMEN (INSULIN ASPART/INSULIN ASPART PROTAMINE 30/70) IN TYPE 2 DIABETES PATIENTS FOLLO...
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014803-30 Sponsor Protocol Number: H9X-MC-GBDB Start Date*: 2010-06-09
    Sponsor Name:Lilly S.A.
    Full Title: Estudio abierto, aleatorizado, con dos ramas paralelas, comparativo de no inferioridad de los efectos de dos dosis de LY2189265 versus insulina glargina sobre el control glucémico en pacientes con ...
    Medical condition: Diabetes Mellitus tipo 2
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) FR (Completed) HU (Completed) SK (Completed) CZ (Completed) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006706-14 Sponsor Protocol Number: DE-PIO-028 Start Date*: 2008-07-29
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001942-24 Sponsor Protocol Number: HypoDeg Start Date*: 2014-10-23
    Sponsor Name:Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
    Full Title: The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in subjects with type 1 diabetes and high risk of nocturnal severe hypoglycaemia
    Medical condition: Sypmtomatic nocturnal hypoglycaemia in subjects with type 1 diabetes and high risk of nocturnal severe hypoglyceamia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018437-21 Sponsor Protocol Number: LANTU_C_03680 Start Date*: 2010-06-07
    Sponsor Name:SANOFI AVENTIS GROUPE
    Full Title: A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated ...
    Medical condition: Type 2 diabetes not adequately controlled
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) FR (Completed) NL (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002135-17 Sponsor Protocol Number: GBB17 Start Date*: 2016-02-05
    Sponsor Name:UNIVERSITà DEGLI STUDI DI PERUGIA
    Full Title: Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes.
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045234 Type I diabetes mellitus with other specified manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002474-60 Sponsor Protocol Number: NN1250-1835 Start Date*: 2007-11-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 16 week randomised, open labelled, 3-armed, treat-to-target, parallel group trial comparing SIBA (D) once daily + NovoRapid®, SIBA (E) once daily + NovoRapid® and insulin glargine once daily + No...
    Medical condition: type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005334-37 Sponsor Protocol Number: LixiBit Start Date*: 2014-05-23
    Sponsor Name:Medical University of Vienna / Medizinische Universität Wien
    Full Title: Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targe...
    Medical condition: 10 patients (both gender) under treatment with premixed insulin (2-3 injections) and HbA1c>7% will be switched to basal insulin glargine (Lantus, once daily) and GLP-1 receptor agonist Lixisenatide...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000247-26 Sponsor Protocol Number: H7U-MC-IDBA(b) Start Date*: 2006-05-18
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glar...
    Medical condition: Male or female nonsmoking patients 18 years of age or older; have had type 2 diabetes mellitus for at least 6 months at study entry and have been treated with one or more oral antihyperglycemic med...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012641 Diabetic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002418-20 Sponsor Protocol Number: F3Z-MC-IOPE Start Date*: 2007-08-03
    Sponsor Name:Lilly S.A.
    Full Title: Estudio PERSISTENT: Estudio prospectivo y aleatorizado en el que se compara la suspensión de insulina lispro con protamina con la insulina glargina en pacientes con diabetes tipo 2 que reciben medi...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019724-30 Sponsor Protocol Number: F3Z-CR-IOQE Start Date*: 2010-12-17
    Sponsor Name:Lilly S.A.
    Full Title: Comparación de insulina lispro premezclada (proporción baja) dos veces al día frente a insulina glargina una vez al día e insulina lispro prandial una vez al día, como estrategias de intensificació...
    Medical condition: Diabetes tipo 2
    Disease: Version SOC Term Classification Code Term Level
    13 10067585 Diabetes mellitus tipo 2 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001918-34 Sponsor Protocol Number: ClinDiab-02 Start Date*: 2011-05-19
    Sponsor Name:Medizinische Universität Graz
    Full Title: An open, single-centre, controlled trial to investigate the efficacy and usability of published best practice to control glycaemia in hospitalised patients with type 2 diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 30 21:11:00 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA